Neurogene’s NGN-401: Strong Clinical Results and Market Misalignment Justify Buy Rating

Tip Ranks

2025.11.17 11:35

I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene, setting a $70 price target. The strong clinical results of NGN-401, especially for Rett syndrome, show significant improvements, yet the market undervalues it due to misinterpretations. Kapoor views the recent selloff as narrative noise, not reflective of NGN-401's potential. Insights from Dr. David Lieberman highlight its safety and long-term benefits, supporting Kapoor's positive outlook.

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $70.00.

Meet Your ETF AI Analyst

Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Neurogene’s potential despite its current undervaluation. The clinical results for NGN-401, particularly in the treatment of Rett syndrome, are compelling, showing deep and durable improvements across multiple domains without regression. This is evidenced by six out of eight patients surpassing the pivotal responder threshold, demonstrating more validated skill gains with fewer patients compared to competitors.
Kapoor notes that the market’s current valuation does not reflect these clinical successes, partly due to misinterpretations by some analysts rather than genuine investor skepticism. The recent selloff is seen as narrative noise, not a reflection of NGN-401’s clinical trajectory, which remains strong and promising. Furthermore, insights from a well-attended KOL call with Dr. David Lieberman emphasized the safety and long-term benefits of NGN-401, reinforcing its potential for adoption in irreversible gene therapies. This combination of clinical strength and market misalignment underpins Kapoor’s Buy rating and the 12-month price target of $70.